CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding ...

HG202 is the first CRISPR/Cas13Y RNA-targeting therapy to enter clinical development and the only clinical-stage CRISPR RNA-editing therapy for age-related macular degeneration Preclinical studies ...

Barclays lowered the firm’s price target on Crispr Therapeutics (CRSP) to $55 from $59 and keeps an Equal Weight rating on the shares.

CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of DNA with elegant precision. But it turns out that CRISPR systems have more ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) on November 5 and set a ...

Heritable human genome editing has long been hotly contested, in large part because of its societal and eugenic implications ...

The role of RNA in a function called RNA interference — where small RNA molecules keep a gene from being expressed — has been ...

CRISPR Therapeutics recently proved it was capable of getting a drug approved. Next, its oncology and cardiovascular disease programs will need to show value. It may soon face some financial ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Dr. Jennifer Doudna is Optimistic About Future Applications of Gene-Editing Technology ...